PL409699A1 - Pharmaceutical composition containing nystatin and beta-escine or pharmaceutically allowable salts thereof and its application - Google Patents

Pharmaceutical composition containing nystatin and beta-escine or pharmaceutically allowable salts thereof and its application

Info

Publication number
PL409699A1
PL409699A1 PL409699A PL40969914A PL409699A1 PL 409699 A1 PL409699 A1 PL 409699A1 PL 409699 A PL409699 A PL 409699A PL 40969914 A PL40969914 A PL 40969914A PL 409699 A1 PL409699 A1 PL 409699A1
Authority
PL
Poland
Prior art keywords
pharmaceutical composition
escine
beta
application
composition containing
Prior art date
Application number
PL409699A
Other languages
Polish (pl)
Other versions
PL230633B1 (en
Inventor
Roman Franiczek
Michał Gleńsk
Barbara Krzyżanowska
Maciej Włodarczyk
Original Assignee
Uniwersytet Medyczny Im. Piastów Śląskich We Wrocławiu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Medyczny Im. Piastów Śląskich We Wrocławiu filed Critical Uniwersytet Medyczny Im. Piastów Śląskich We Wrocławiu
Priority to PL409699A priority Critical patent/PL230633B1/en
Publication of PL409699A1 publication Critical patent/PL409699A1/en
Publication of PL230633B1 publication Critical patent/PL230633B1/en

Links

Abstract

Wynalazek dotyczy kompozycji farmaceutycznej zawierającej nystatynę oraz ß-escynę lub ich dopuszczalne farmaceutycznie sole, wykazującej działanie synergistyczne w leczeniu lub zapobieganiu zakażeniom grzybiczym wywołanym szczepami Candida, zwłaszcza C. glabrata.The invention relates to a pharmaceutical composition comprising nystatin and ß-escin or pharmaceutically acceptable salts thereof, exhibiting synergistic effects in the treatment or prevention of fungal infections caused by Candida strains, in particular C. glabrata.

PL409699A 2014-10-03 2014-10-03 Pharmaceutical composition containing nystatin and beta-escine or pharmaceutically allowable salts thereof and its application PL230633B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL409699A PL230633B1 (en) 2014-10-03 2014-10-03 Pharmaceutical composition containing nystatin and beta-escine or pharmaceutically allowable salts thereof and its application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL409699A PL230633B1 (en) 2014-10-03 2014-10-03 Pharmaceutical composition containing nystatin and beta-escine or pharmaceutically allowable salts thereof and its application

Publications (2)

Publication Number Publication Date
PL409699A1 true PL409699A1 (en) 2016-04-11
PL230633B1 PL230633B1 (en) 2018-11-30

Family

ID=55646122

Family Applications (1)

Application Number Title Priority Date Filing Date
PL409699A PL230633B1 (en) 2014-10-03 2014-10-03 Pharmaceutical composition containing nystatin and beta-escine or pharmaceutically allowable salts thereof and its application

Country Status (1)

Country Link
PL (1) PL230633B1 (en)

Also Published As

Publication number Publication date
PL230633B1 (en) 2018-11-30

Similar Documents

Publication Publication Date Title
PH12016501790A1 (en) Pharmaceutical compositions of therapeutically active compounds
MA39986A (en) Purine derivatives as cd73 inhibitors for the treatment of cancer
PH12016501788A1 (en) Pharmaceutical compositions of therapeutically active compounds
IN2014DN10670A (en)
EA201791454A1 (en) DRUG FORMS FOR TRANSDERMAL ADMINISTRATION
IN2013MU03583A (en)
TR201821116A2 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING POSACONAZOL AND THE MANUFACTURING METHOD
MX2017003928A (en) Long acting pharmaceutical compositions.
EA201890364A1 (en) COMPOUNDS SUITABLE FOR INHIBITING ROR-GAMMA-t
EA201692020A1 (en) PROTECTIVE MEANS OF AMERICA ACID FOR APPLICATION IN THE TREATMENT OF LACTOACIDOSIS OR INDIVIDUAL BY MEDICINAL MEANS OF THE DIFFERENT ACTION DUE TO THE COMPLEX I AND OXIDATIVE DISORDERS OF OXIDATIVE CHEMICAL REFERENCES AGREES
IN2014CH00840A (en)
EA201691792A1 (en) PHARMACEUTICAL COMPOSITIONS BASED ON VILDAGLIPTINA
FI3445331T3 (en) Preservative free pharmaceutical ophthalmic compositions
MX2015013755A (en) Pharmaceutical formulation for use in the treatment and/or prevention of restenosis.
NZ757526A (en) Naphthoquinones, their derivatives and uses thereof in methods for the treatment of mitochondrial dysfunction
MX2015013151A (en) Methods of treating dyskinesia and related disorders.
WO2016020408A3 (en) Compounds for preventing ototoxicity
PH12018500579A1 (en) Fungal keratitis prophylactic or therapeutic agent
EA201791483A1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MYCOSIS
EA201501130A1 (en) OPHTHALMOLOGIC PHARMACEUTICAL COMPOSITION
EP3162369A4 (en) Pharmaceutical composition containing fk506 derivative for treating fungal infection caused by genus cryptococcus and genus candida and use thereof
EA201790020A1 (en) COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THEIR APPLICATION IN THE TREATMENT OF NEURODEGENERATIVE DISEASES
PL409699A1 (en) Pharmaceutical composition containing nystatin and beta-escine or pharmaceutically allowable salts thereof and its application
MX2018004532A (en) Combination of trazodone and gabapentin for the treatment of pain.
EA201891848A1 (en) PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF FIBROSIS